The manipulator behind “Scissors”: γ -secretase and its modulators in Alzheimer’s disease
Authors:
Open Access
- 25 August 2025
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 17, 1637671
Abstract
The intramembrane aspartic protease, γ-secretase, is a heterotetrameric protein complex composed of four integral membrane proteins: presenilin (PSEN), nicastrin (NCT), Anterior pharynx defective-1 (APH-1), and presenilin enhancer 2 (PEN-2). These components are sequentially assembled into a functional complex. γ-secretase is ubiquitously expressed in all cells and tissues and exhibits enzymatic activity akin to “molecular scissors” by cleaving various type I transmembrane proteins. The primary substrates of this complex include amyloid precursor protein (APP) and Notch. The role of APP in the pathogenesis of Alzheimer’s disease (AD) has been extensively investigated. Although γ-secretase inhibitors (GSIs) have been evaluated for their therapeutic potential in AD, their clinical application is limited due to significant toxic side effects. Recently, γ-secretase modulators (GSMs) have emerged as promising alternatives, offering new opportunities for the treatment of AD, especially the inherent γ-secretase modulatory proteins (GSMPs) within cells. Research on GSMPs has ushered in a new era for mitigating the side effects of AD drugs. In this review, we systematically summarize recent advancements in the study of γ-secretase in relation to AD and provide an overview of GSMs and GSMPs, thereby offering potential insights for the development of therapeutic strategies for AD.Keywords
Funding Information
- National Natural Science Foundation of China (32360162)
- Education Department of Shaanxi Province
This publication has 288 references indexed in Scilit:
- γ‐Secretase Modulator BPN15606 Reduced Aβ42 and Aβ40 and Countered Alzheimer‐Related Pathologies in a Mouse Model of Down SyndromeAnnals of Neurology, 2024
- Endotype reversal as a novel strategy for screening drugs targeting familial Alzheimer's diseaseAlzheimer's & Dementia, 2022
- Pharmacokinetic and Pharmacodynamic Effects of a γ‐Secretase Modulator, PF‐06648671, on CSF Amyloid‐β Peptides in Randomized Phase I StudiesClinical Pharmacology & Therapeutics, 2019
- Brain ischaemia induces shedding of a BDNF‐scavenger ectodomain from TrkB receptors by excitotoxicity activation of metalloproteinases and γ‐secretasesThe Journal of Pathology, 2015
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel γ-secretase modulator, E2212, in healthy human subjectsThe Journal of Clinical Pharmacology, 2014
- The therapeutics of Alzheimer's disease: Where we stand and where we are headingAnnals of Neurology, 2013
- Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer DiseaseA Randomized Controlled TrialJAMA, 2009
- Decreased levels of PSD95 and two associated proteins and increased levels of BCl2 and caspase 3 in hippocampus from subjects with amnestic mild cognitive impairment: Insights into their potential roles for loss of synapses and memory, accumulation of Aβ, and neurodegeneration in a prodromal stage of Alzheimer's diseaseJournal of Neuroscience Research, 2009
- A γ‐secretase inhibitor decreases amyloid‐β production in the central nervous systemAnnals of Neurology, 2009
- Genetic Association of Neurotrophic Tyrosine Kinase Receptor Type 2 (NTRK2) With Alzheimer's DiseaseAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007